Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.

[1]  B. Hammock,et al.  Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases☆ , 2017, Pharmacology & therapeutics.

[2]  R. Tal-Singer,et al.  Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers , 2017, Chest.

[3]  S. Vannier,et al.  Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. , 2016, The New England journal of medicine.

[4]  Joseph Cheriyan,et al.  Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. , 2016, British journal of clinical pharmacology.

[5]  E. Schaper.  Bial incident raises FAAH suspicions , 2016, Nature Biotechnology.

[6]  D. Piomelli,et al.  Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies. , 2016, European journal of medicinal chemistry.

[7]  F. Haj,et al.  Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice. , 2015, Toxicology and applied pharmacology.

[8]  F. Haj,et al.  Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain , 2015, Proceedings of the National Academy of Sciences.

[9]  D. Piomelli,et al.  Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive. , 2015, Pharmacological research.

[10]  M. Dehghan.  Comparative Effectiveness of B and E Vitamins with Diclofenac in Reducing Pain Due to Osteoarthritis of the Knee , 2015, Medical archives.

[11]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[12]  S. Hwang,et al.  Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure. , 2014, American journal of physiology. Heart and circulatory physiology.

[13]  Jun Yang,et al.  An omega‐3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin II‐dependent hypertension (832.5) , 2014, Journal of cardiovascular pharmacology.

[14]  D. Piomelli,et al.  Peripheral gating of pain signals by endogenous lipid mediators , 2014, Nature Neuroscience.

[15]  Devyn M. Smith,et al.  CHAPTER 1:The Disease of Pain and Current Market Trends , 2013 .

[16]  G. F. Ruda,et al.  Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors. , 2013, Journal of medicinal chemistry.

[17]  B. Hammock,et al.  Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis. , 2013, Veterinary anaesthesia and analgesia.

[18]  B. Cravatt,et al.  Chemical Probes of Endocannabinoid Metabolism , 2013, Pharmacological Reviews.

[19]  Paul D. Jones,et al.  Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models. , 2013, European journal of pharmacology.

[20]  B. Hammock,et al.  Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. , 2013, Annual review of pharmacology and toxicology.

[21]  Shuxing Zhang,et al.  Polypharmacology: drug discovery for the future , 2013, Expert review of clinical pharmacology.

[22]  Jun Yang,et al.  Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. , 2012, American journal of respiratory cell and molecular biology.

[23]  P. Potter,et al.  Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597. , 2012, Biochemical pharmacology.

[24]  T. Smart,et al.  An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee , 2012, PAIN®.

[25]  B. Hammock,et al.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. , 2012, Journal of medicinal chemistry.

[26]  B. Hammock,et al.  Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys , 2012, British journal of pharmacology.

[27]  B. Hammock,et al.  Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. , 2011, Prostaglandins & other lipid mediators.

[28]  S. Hwang,et al.  Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. , 2011, Journal of medicinal chemistry.

[29]  B. Hammock,et al.  Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP , 2011, Proceedings of the National Academy of Sciences.

[30]  Shobha N. Bhattachar,et al.  Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. , 2011, ACS medicinal chemistry letters.

[31]  B. Hammock,et al.  Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids[S] , 2010, Journal of Lipid Research.

[32]  B. Cravatt,et al.  Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). , 2009, Bioorganic & medicinal chemistry letters.

[33]  Raymond C Stevens,et al.  Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. , 2009, Chemistry & biology.

[34]  Paul D. Jones,et al.  Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways , 2008, Proceedings of the National Academy of Sciences.

[35]  Sandy J. Wilson,et al.  Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. , 2008, Bioorganic & medicinal chemistry letters.

[36]  Paul D. Jones,et al.  Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH). , 2008, Bioorganic & medicinal chemistry.

[37]  Marya Liimatta,et al.  Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. , 2007, Biochemistry.

[38]  J. Brioni,et al.  Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets , 2007, Neuropharmacology.

[39]  B. Hammock,et al.  Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. , 2006, Life sciences.

[40]  B. Hammock,et al.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Gaetani,et al.  Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3′-Carbamoyl-biphenyl-3-yl Ester (URB597): Effects on Anandamide and Oleoylethanolamide Deactivation , 2005, Journal of Pharmacology and Experimental Therapeutics.

[42]  Giovanni Piersanti,et al.  Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. , 2004, Journal of medicinal chemistry.

[43]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[44]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Casida,et al.  Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides. , 2001, Toxicology and applied pharmacology.

[46]  B D Hammock,et al.  Soluble Epoxide Hydrolase Regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic Acids , 2000, Circulation research.

[47]  A. Orekhov,et al.  Paraoxonase and atherosclerosis-related cardiovascular diseases. , 2017, Biochimie.

[48]  T. Fukami,et al.  The emerging role of human esterases. , 2012, Drug metabolism and pharmacokinetics.

[49]  B. Hammock,et al.  Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. , 2007, Bioorganic & medicinal chemistry.

[50]  B. Hammock,et al.  Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. , 2005, Annual review of pharmacology and toxicology.